POCKET HANDBOOK OF GI PHARMACOTHERAPEUTICS
|
|
- Deborah Hines
- 5 years ago
- Views:
Transcription
1 POCKET HANDBOOK OF GI PHARMACOTHERAPEUTICS
2 CLINICAL GASTROENTEROLOGY GEORGE Y. WU, SERIES EDITOR For other titles published in this series, go to
3 POCKET HANDBOOK OF GI PHARMACOTHERAPEUTICS Edited by GEORGE Y. WU, MD, PHD University of Connecticut Health Center, Farmington, CT and ACHILLES PAPPANO, PHD University of Connecticut Health Center, Farmington, CT
4 Editors George Y. Wu, MD, PhD Achilles Pappano, PhD Department of Gastroenterology Department of Cell Biology University of Connecticut University of Connecticut Health Center Health Center Farmington, CT Farmington, CT USA USA ISBN: e-isbn: DOI: / Library of Congress Control Number: Humana Press, a part of Springer Science + Business Media, LLC 2009 All rights reserved. This work may not be translated or copied in whole or in part without the written permission of the publisher (Humana Press, c/o Springer Science + Business Media, LLC, 233 Spring Street, New York, NY 10013, USA), except for brief excerpts in connection with reviews or scholarly analysis. Use in connection with any form of information storage and retrieval, electronic adaptation, computer software, or by similar or dissimilar methodology now known or hereafter developed is forbidden. The use in this publication of trade names, trademarks, service marks, and similar terms, even if they are not identified as such, is not to be taken as an expression of opinion as to whether or not they are subject to proprietary rights. While the advice and information in this book are believed to be true and accurate at the date of going to press, neither the authors nor the editors nor the publisher can accept any legal responsibility for any errors or omissions that may be made. The publisher makes no warranty, express or implied, with respect to the material contained herein. Printed on acid-free paper springer.com
5 PREFACE The number of agents for the treatment of digestive diseases and conditions has increased greatly, and in some cases, one is confronted with a bewildering array of brand and generic names. Although databases and reference books provide detailed information on pharmacology, toxicology, and therapeutics, obtaining commonly needed information, such as recommended first line agents, dosage, duration, side effects, and drug interactions, requires sifting through other materials. There is no text that contains just this practical pharmacological information. The purpose of this project is to remedy this deficiency with a small portable text. Because treatment questions generally begin with diagnoses, each chapter addresses therapy of a digestive disease or condition, listed in the contents. Treatment algorithms are provided where available. Agents recommended for treatment of the condition are described in detail, including brand and generic names, indications, contraindications, side effects, drug interactions, doses/ routes of administration, durations, and approximate costs. In addition, an index at the end of this handbook lists all the drugs in alphabetical order for those interested in specific agents. Although the physical characteristics enhance its portability and convenience, as with other books in this series, we believe that the practical clinical information presented in this simple format will be of greatest value. George Y. Wu Achilles Pappano Farmington, Connecticut July 22, 2008 v
6 CONTENTS Preface George Y. Wu, Achilles Pappano v Contributors ix I Gastroesophageal Diseases 1 Peptic Disorders Lisa Rossi and Shishir Mathur 2 Gastrointestinal Bleeding Lisa Rossi and Shishir Mathur 3 General GI Motility Disorders Lisa Rossi 4 Specific GI Motility Disorders Lisa Rossi and Shishir Mathur 5 Inflammatory Bowel Disease Shilpa Madadi and Shishir Mathur 6 General GI Infections Marcy Coash and Shishir Mathur 7 Specific GI Microbial Infections Shilpa Madadi, Vivian Teixeira, and Shishir Mathur II Liver Disease 8 Hepatitis Shilpa Madadi and Shishir Mathur 9 Cholestasis Shishir Mathur 10 Hepatic Encephalopathy Shilpa Madadi and Shishir Mathur vii
7 viii Contents 11 Pruritis Marcy Coash 12 Nutrition and Enzyme Deficiency Shishir Mathur References Index
8 CONTRIBUTORS Marcy Coash, md Internal Medicine Residency Program, University of Connecticut Health Center, Farmington, CT Shilpa Madadi, md Gastroenterology Fellowship Program, University of Connecticut Health Center, Farmington, CT Shishir Mathur, mbbs Internal Medicine Residency Program, University of Connecticut Health Center, Farmington, CT Achilles Pappano, phd Department of Cell Biology, University of Connecticut Health Center, Farmington, CT Vivian Teixeira, md Primary Care Residency Program, University of Connecticut Health Center, Farmington, CT Lisa Rossi, md Department of Gastroenterology, Saint Francis Hospital and Medical Center, Hartford, CT George Wu, md, phd Department of Gastroenterology, University of Connecticut Health Center, Farmington, CT ix
9 I Gastroesophageal Diseases
10 1 Peptic Disorders Lisa Rossi, MD and Shishir Mathur, MBBS CONTENTS Gastroesophageal Reflux Disorder (GERD) and Peptic Ulcer Disease (PUD) Proton Pump Inhibitors Histamine H2 Antagonists Other Agents Helicobacter Pylori From: Clinical Gastroenterology: Pocket HandBook of GI Pharmacotherapeutics Edited by: G.Y. Wu and A. Pappano, DOI: / _1, Humana Press, a part of Springer Science + Business Media, LLC
11 4 Rossi and Mathur GASTROESOPHAGEAL REFLUX DISORDER (GERD) AND PEPTIC ULCER DISEASE (PUD) Patient with GERD Lifestyle modifications Treatment with proton pump inhibitor for 2 weeks Symptoms resolve consider stopping therapy No Improvement Long term therapy Consider motility agents Consider ph monitoring Recurrence of symptoms Consider surgery, endoscopic therapy in select patients PROTON PUMP INHIBITORS Omeprazole Trade name: Prilosec, Prilosec OTC Manufacturer: AstraZeneca, Proctor and Gamble, generic Dosage: GERD/erosive esophagitis: 20 mg p.o. q.d. for 4 weeks Gastric ulcer: 40 mg p.o. q.d. for up to 4 8 weeks Duodenal ulcer: mg p.o. q.d. for 4 8 weeks Helicobacter pylori infection: 20 mg p.o. b.i.d. in conjunction with triple therapy Stress ulcer prophylaxis: 40 mg p.o. q.d. initially, then mg daily Gastric hypersecretion: 60 mg p.o. q.d. initial dose, increase up to 120 mg p.o. t.i.d.
12 Chapter 1 / Peptic Disorders 5 Contraindications/cautions: Hypersensitivity to omeprazole Caution in hypocalcemia, hypokalemia, metabolic alkalosis, respiratory alkalosis, Bartter s syndrome (powder for oral suspension contains 1,680 mg or 20 meq of sodium bicarbonate) Adverse effects: Gastrointestinal: Abdominal pain, diarrhea, pancreatitis, hepatotoxicity Neurologic: Headache Renal: Interstitial nephritis Musculoskeletal: Hip fracture, rhabdomyolysis Drug interactions: Increases levels of warfarin, cyclosporine, digoxin, phenytoin Decreases levels of atazanavir, ketoconazole, itraconazole, cefuroxime Pregnancy category: C Lactation: Probably safe Relative cost: ($$) Esomeprazole Magnesium (Oral) Esomeprazole Sodium (IV) Brand name: Nexium Manufacturer: AstraZeneca Dosages: GERD/erosive esophagitis: mg p.o. q.d. for treatment Maintenance therapy in GERD/erosive esophagitis: 20 mg p.o. q.d. Gastric ulcer: mg p.o. q.d. for up to 6 months Acute non-variceal upper gastrointestinal (GI) bleed: 80 mg i.v. bolus followed by continuous infusion at 8 mg/h. for 72 h. after endoscopic therapy H. pylori infection: 40 mg p.o. q.d. in conjunction with triple therapy Zollinger-Ellison syndrome: 40 mg b.i.d. increase up to 240 mg per day based on symptoms Contraindications/cautions: Hypersensitivity to esomeprazole or benzimidazoles Caution with liver disease Adverse effects: Gastrointestinal: Abdominal pain, constipation, diarrhea, flatulence, nausea, pancreatitis (rare) Neurologic: Headache Dermatologic: Erythema multiforme, Stevens-Johnson syndrome, toxic epidermal necrolysis Musculoskeletal: Hip fracture, rhabdomyolysis
Chronic Pain. For other titles published in this series, go to
Chronic Pain For other titles published in this series, go to www.springer.com/series/7633 Dawn A. Marcus, M.D. Chronic Pain A Primary Care Guide to Practical Management Second Edition Dawn A. Marcus,
More informationColor Atlas of High Resolution Manometry
Color Atlas of High Resolution Manometry Color Atlas of High Resolution Manometry Edited by Jeffrey Conklin, MD GI Motility Program Mark Pimentel, MD, FRCP(C) Cedars-Sinai Medical Center Edy Soffer, MD
More informationECG INTERPRETATION: FROM PATHOPHYSIOLOGY TO CLINICAL APPLICATION
ECG INTERPRETATION: FROM PATHOPHYSIOLOGY TO CLINICAL APPLICATION ECG INTERPRETATION: FROM PATHOPHYSIOLOGY TO CLINICAL APPLICATION by Fred Kusumoto, MD Electrophysiology and Pacing Service Division of Cardiovascular
More information2 Gastrointestinal Bleeding
2 Gastrointestinal Bleeding Lisa Rossi, MD and Shishir Mathur, MBBS C ONTENTS Acute Non-Variceal Upper Gastrointestinal Bleeding Acute Hemorrhage from Esophageal Varices ACUTE NON-VARICEAL UPPER GASTROINTESTINAL
More informationProton Pump Inhibitors (PPIs) (Sherwood Employer Group)
Proton Pump Inhibitors (PPIs) (Sherwood Employer Group) BCBSKS will review Prior Authorization requests Prior Authorization Form: https://www.bcbsks.com/customerservice/forms/pdf/priorauth-6058ks-st-ippi.pdf
More informationMaurie Markman, MD, Series Editor
Palliative Care Current Clinical Oncology Maurie Markman, MD, Series Editor For other titles published in this series, go to www.springer.com/series/7631 Palliative Care A Ca s e-b a s e d Gu i d e Edited
More informationEMILOK Global. (omeprazole) Composition: Each capsule contains 20 mg omeprazole as enteric-coated
EMILOK Global (omeprazole) Composition: Each capsule contains 20 mg omeprazole as enteric-coated granules. Properties: Emilok (omeprazole) belongs to the group of proton pump inhibitors, inhibits both
More informationFrozen Section Library Series Editor Philip T. Cagle, MD Houston, Texas, USA
Frozen Section Library Series Editor Philip T. Cagle, MD Houston, Texas, USA For further volumes, go to http://www.springer.com/series/7869 Frozen Section Library: Central Nervous System Richard A. Prayson
More informationHandbook of Pediatric Eye and Systemic Disease
Handbook of Pediatric Eye and Systemic Disease Handbook of Pediatric Eye and Systemic Disease Edited by Kenneth W. Wright, MD Director, Wright Foundation for Pediatric Ophthalmology Director, Pediatric
More informationEU RISK MANAGEMENT PLAN (EU RMP)
EU RISK MANAGEMENT PLAN (EU RMP) Active substance(s) (INN or common name): Esomeprazole Pharmaco-therapeutic group (ATC Code): A02B C05 Name of Marketing Authorisation Holder or Applicant: Strength and
More informationProton Pump Inhibitors. Description. Section: Prescription Drugs Effective Date: July 1, 2014
Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 5.09.01 Subject: Proton Pump Inhibitors Page: 1 of 7 Last Review Date: June 12, 2014 Proton Pump Inhibitors
More informationDyspepsia in Clinical Practice
Dyspepsia in Clinical Practice wwwwwwwwwwwwwwwww Dyspepsia in Clinical Practice Marko Duvnjak Editor Marko Duvnjak Department of Gastroenterology and Hepatology University Hospital Sestre milosrdnice Medical
More informationGASTROINTESTINAL AND ANTIEMETIC DRUGS. Submitted by: Shaema M. Ali
GASTROINTESTINAL AND ANTIEMETIC DRUGS Submitted by: Shaema M. Ali GASTROINTESTINAL AND ANTIEMETIC DRUGS by: Shaema M. Ali There are four common medical conditions involving the GI system 1) peptic ulcers
More informationDeath Threats and Violence
Death Threats and Violence Stephen J. Morewitz Death Threats and Violence New Research and Clinical Perspectives Stephen J. Morewitz San Francisco, California Tarzana, California Buffalo Grove, Illinois
More informationFrozen Section Library: Lung
Frozen Section Library: Lung FROZEN SECTION LIBRARY SERIES Philip T. Cagle, MD, Series Editor 1. Timothy Craig Allen, Philip T. Cagle: Frozen Section Library: Lung 2009 ISBN 978-0-387-09572-1 Frozen Section
More informationProton Pump Inhibitors. Description
Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 5.50.01 Subject: Proton Pump Inhibitors Page: 1 of 6 Last Review Date: June 24, 2015 Proton Pump Inhibitors
More informationThe Pharmacology of Alcohol and Drugs of Abuse and Addiction
The Pharmacology of Alcohol and Drugs of Abuse and Addiction Norman S. Miller The Pharmacology of Alcohol and Drugs of Abuse and Addiction Springer-Verlag New York Berlin Heidelberg London Paris Tokyo
More informationDrug Class Monograph
Drug Class Monograph Class: Proton Pump Inhibitors Drugs: Aciphex Sprinkle (rabeprazole), Dexilant (dexlansoprazole), Lansoprazole, Nexium (esomeprazole capsule, esomeprazole granules), Omeprazole, Pantoprazole,
More informationDifference between omeprazole and omeprazole delayed release
Cari untuk: Cari Cari Difference between omeprazole and omeprazole delayed release 7-2-2018 Easy to read patient leaflet for Omeprazole Delayed-Release Capsules. Includes indications, proper use, special
More informationCancer Treatment and Research
Cancer Treatment and Research Volume 155 Series Editor Steven T. Rosen For further volumes: http://www.springer.com/series/5808 Boris Pasche Editor Cancer Genetics 123 Editor Boris Pasche, MD, PhD, FACP
More informationCLINICAL GASTROENTEROLOGY
CLINICAL GASTROENTEROLOGY Series Editor George Y. Wu University of Connecticut Health Center, Farmington, CT, USA For further volumes: http://www.springer.com/series/7672 Elizabeth J. Carey Keith D. Lindor
More informationSee Important Reminder at the end of this policy for important regulatory and legal information.
Clinical Policy: Reference Number: CP.CPA.209 Effective Date: 11.16.16 Last Review Date: 11.17 Line of Business: Medicaid Medi-Cal Revision Log See Important Reminder at the end of this policy for important
More informationManagement of Headache and Headache Medications
Management of Headache and Headache Medications Lawrence D. Robbins, M.D. Management of Headache and Headache Medications Foreword by Jerome Goldstein, M.D. Springer-Verlag New York Berlin Heidelberg London
More informationFrozen Section Library: Pleura
Frozen Section Library: Pleura For other titles published in this series, go to www.springer.com/series/7869 Frozen Section Library: Pleura Philip T. Cagle, MD Weill Medical College of Cornell University,
More informationCopy right protected Page 1
DRUGS USED IN ULCERS AND GIT DISORDERS A peptic ulcer, also known as PUD or peptic ulcer disease is an ulcer of an area of the gastrointestinal tract that is usually acidic and thus extremely painful.
More informationAMERICAN JOINT COMMITTEE ON CANCER AJCC CANCER STAGING
AMERICAN JOINT COMMITTEE ON CANCER AJCC CANCER STAGING ATLAS EDITORS FREDERICK L. GREENE, m.d. Chair, Department of General Surgery Carolinas Medical Center Charlotte, North Carolina CAROLYN C. COMPTON,
More informationPercutaneous Laser Disc Decompression
Percutaneous Laser Disc Decompression , MD Assistant Clinical Professor of Medicine, Columbia University College of Physicians & Surgeons, New York, New York; and Director of Laser Spine Center, New York,
More informationDifferential Diagnosis of Movement Disorders in Clinical Practice
Differential Diagnosis of Movement Disorders in Clinical Practice Abdul Qayyum Rana Peter Hedera Differential Diagnosis of Movement Disorders in Clinical Practice Abdul Qayyum Rana Parkinson's Clinic
More informationJohn Papadopoulos David R. Schwartz Consulting Editor. Pocket Guide to Critical Care Pharmacotherapy Second Edition
John Papadopoulos David R. Schwartz Consulting Editor Pocket Guide to Critical Care Pharmacotherapy Second Edition 123 Pocket Guide to Critical Care Pharmacotherapy John Papadopoulos Author David R. Schwartz
More informationCongenital Hip Disease in Adults
Congenital Hip Disease in Adults George Hartofilakidis George C. Babis Kalliopi Lampropoulou-Adamidou Congenital Hip Disease in Adults George Hartofilakidis, MD, FACS Orthopaedic Department Medical School
More informationRecent Research in Psychology
Recent Research in Psychology 1.0. Fisher R.C. Silver 1.M. Chinsky B. Goff Y. Klar Evaluating a Large Group Awareness Training A Longitudinal Study of Psychosocial Effects Springer-Verlag New York Berlin
More information0BCore Safety Profile. Pharmaceutical form(s)/strength: Losec MUPS tablets 10, 20 mg (OTC) NL/H/PSUR/0058/001 Date of FAR:
0BCore Safety Profile Active substance: Omeprazole Pharmaceutical form(s)/strength: Losec MUPS tablets 10, 20 mg (OTC) P-RMS: NL/H/PSUR/0058/001 Date of FAR: 13.06.2013 4.2 Posology and method of administration
More informationRABEPRAZOL 10mg and 20mg Gastro-resistant Tablets
PACKAGE LEAFLET: INFORMATION FOR THE USER RABEPRAZOL 10mg and 20mg Gastro-resistant Tablets RABEPRAZOLE This leaflet is a copy of the Summary of Product Characteristics and Patient Information Leaflet
More informationLouise Grech Alan Lau Editors. Pharmaceutical Care Issues of Patients with Rheumatoid Arthritis. From Hospital to Community
Louise Grech Alan Lau Editors Pharmaceutical Care Issues of Patients with Rheumatoid Arthritis From Hospital to Community Pharmaceutical Care Issues of Patients with Rheumatoid Arthritis Louise Grech
More informationUrinary Tract Infection
Urinary Tract Infection Abhay Rané Ranan Dasgupta Editors Urinary Tract Infection Clinical Perspectives on Urinary Tract Infection Editors Abhay Rané, MS, FRCS, FRCS (Urol) Department of Urology Surrey
More informationGI Pharmacology. Dr. Alia Shatanawi 5/4/2018
GI Pharmacology Dr. Alia Shatanawi 5/4/2018 Drugs Used in Gastrointestinal Diseases Drugs used in Peptic Ulcer Diseases. Drugs Stimulating Gastrointestinal Motility &Laxatives. Antidiarrheal Agents. Drugs
More informationThe usual dose is 40 mg daily with amoxycillin 1.5 g (750 mg b.d.) for 2 weeks. Up to 2 g/day of amoxycillin has been used in clinical trials.
Name Gasec - 2 Gastrocaps Composition Gasec-20 Gastrocaps Each Gastrocaps contains: Omeprazole 20 mg (in the form of enteric-coated pellets) Properties, effects Proton Pump Inhibitor Omeprazole belongs
More informationNEXIUM 40 mg esomeprazole Powder for solution for injection/infusion
NEXIUM 40 mg esomeprazole Powder for solution for injection/infusion Qualitative and Quantitative Composition Each vial contains esomeprazole 40 mg. (as sodium salt) Pharmaceutical form Powder for solution
More informationA Guide to Gastrointestinal Motility Disorders
A Guide to Gastrointestinal Motility Disorders Albert J. Bredenoord André Smout Jan Tack A Guide to Gastrointestinal Motility Disorders Albert J. Bredenoord Gastroenterology and Hepatology Academic Medical
More informationSpringerBriefs in Child Development
SpringerBriefs in Child Development For further volumes: http://www.springer.com/series/10210 Daniel F. Shreeve Reactive Attachment Disorder A Case-Based Approach Daniel F. Shreeve The Carilion Clinic
More informationProton Pump Inhibitors Drug Class Prior Authorization Protocol
Proton Pump Inhibitors Drug Class Prior Authorization Protocol Line of Business: Medi-Cal P&T Approval Date: November 15, 2017 Effective Date: January 1, 2018 This policy has been developed through review
More informationCross-Sectional Anatomy for Computed Tomography
Cross-Sectional Anatomy for Computed Tomography Michael L. Farkas Cross-Sectional Anatomy for Computed Tomography A Self-Study Guide with Selected Sections from Head, Neck, Thorax, Abdomen, and Pelvis
More informationZantac for stomach ulcers
P ford residence southampton, ny Zantac for stomach ulcers Information on the drug ranitidine (Zantac) used in and duodenal ulcers, heartburn, esophagitis, and Zollinger Ellison Syndrome. Side. But with
More informationSUPPORTIVE CARE IN CANCER THERAPY
SUPPORTIVE CARE IN CANCER THERAPY For other titles published in this series, go to www.springer.com/series/7625 SUPPORTIVE CARE IN CANCER THERAPY Edited by DAVID S. ETTINGER, MD The Sidney Kimmel Comprehensive
More informationHODGKIN S AND NON-HODGKIN S LYMPHOMA
HODGKIN S AND NON-HODGKIN S LYMPHOMA edited by JOHN P. LEONARD, MD Center for Lymphoma and Myeloma Weill Medical College of Cornell University New York Presbyterian Hospital New York, NY MORTON COLEMAN,
More information0BCore Safety Profile. Pharmaceutical form(s)/strength: Gastro-resistant capsules (10, 20, 40 mg) NL/H/PSUR/0058/001 Date of FAR:
0BCore Safety Profile Active substance: Omeprazole Pharmaceutical form(s)/strength: Gastro-resistant capsules (10, 20, 40 mg) P-RMS: NL/H/PSUR/0058/001 Date of FAR: 10.04.2013 CSP Drug Substance Omeprazole
More informationMedical and Surgical Complications of Sickle Cell Anemia
Medical and Surgical Complications of Sickle Cell Anemia Ahmed Al-Salem Medical and Surgical Complications of Sickle Cell Anemia Ahmed Al-Salem Department of Surgery Dar A lalafia Medical Company Qatif
More informationRadiology Illustrated
Radiology Illustrated For further volumes: http://www.springer.com/series/11755 In-One Kim Editor Radiology Illustrated: Pediatric Radiology Editor In-One Kim, M.D. Department of Radiology Seoul National
More informationMark W.J. Strachan Brian M. Frier. Insulin Therapy. A Pocket Guide
Insulin Therapy Mark W.J. Strachan Brian M. Frier Insulin Therapy A Pocket Guide Mark W.J. Strachan, MD, FRCP (Ed) Metabolic Unit Western General Hospital Edinburgh United Kingdom Brian M. Frier, MD,
More informationRespiratory Medicine Series Editor: Sharon I.S. Rounds. Marc A. Judson Editor. Pulmonary Sarcoidosis A Guide for the Practicing Clinician
Respiratory Medicine Series Editor: Sharon I.S. Rounds Marc A. Judson Editor Pulmonary Sarcoidosis A Guide for the Practicing Clinician Respiratory Medicine Series Editor: Sharon I.S. Rounds For further
More informationIdentifying, Assessing, and Treating Conduct Disorder at School
Identifying, Assessing, and Treating Conduct Disorder at School Developmental Psychopathology at School Series Editors: Shane R. Jimerson, University of California, Santa Barbara, CA, USA Stephen E. Brock,
More informationNeurobiological Bases of Abnormal Aggression and Violent Behaviour
Neurobiological Bases of Abnormal Aggression and Violent Behaviour . József Haller Neurobiological Bases of Abnormal Aggression and Violent Behaviour József Haller Department of Behavioral Neurobiology
More informationSee Important Reminder at the end of this policy for important regulatory and legal information.
Clinical Policy: (Duexis) Reference Number: CP.PMN.120 Effective Date: 06.01.18 Last Review Date: 05.18 Line of Business: Commercial, Medicaid Revision Log See Important Reminder at the end of this policy
More informationThe Polyol Paradigm and Complications of Diabetes
The Polyol Paradigm and Complications of Diabetes Margo Panush Cohen The Polyol Paradigm and Complications of Diabetes With a Foreword by Harold Rifkin With 25 Figures Springer-Verlag New York Berlin Heidelberg
More informationNexium 24HR. Tools and information for you and your pharmacy team NOW OTC FOR FREQUENT HEARTBURN. Consumer Healthcare Pfizer Inc.
NOW OTC FOR FREQUENT HEARTBURN w e N Nexium 24HR P H A R M A S S I S T K I T Tools and information for you and your pharmacy team 2014 Pfizer Inc. NXM041468 05/14 Q: What is the indication for Nexium 24HR
More informationDeveloping Evidence-Based Best Practices for the Prescribing and Use of Proton Pump Inhibitors in Canada
Developing Evidence-Based Best Practices for the Prescribing and Use of Proton Pump Inhibitors in Canada Presented by: Sumeet R. Singh, COMPUS April 4, 2006 Background COMPUS Objective: To identify and
More informationHandbook of Insulin Therapies
Handbook of Insulin Therapies Winston Crasto Janet Jarvis Melanie J. Davies Handbook of Insulin Therapies Winston Crasto George Eliot Hospital NHS Trust, Nuneaton United Kingdom Janet Jarvis Leicester
More informationBreast Cancer Risk Reduction and Early Detection
Breast Cancer Risk Reduction and Early Detection Edward R. Sauter Mary B. Daly Editors Breast Cancer Risk Reduction and Early Detection 123 Editors Edward R. Sauter University of North Dakota School of
More information* Adults. NSAID associated peptic ulceration: - Acute treatment: 150 mg twice daily for 8 to 12 weeks, or 300mg nocte.
Trade Name Aciloc 75 mg & 300 mg Film-coated tablets Generic Name Ranitidine Composition Each Aciloc 300 mg film-coated tablet contains: - Active ingredient: Ranitidine hydrochloride 336 mg equivalent
More informationPocket Guide to Critical Care Pharmacotherapy
Pocket Guide to Critical Care Pharmacotherapy John Papadopoulos Author David R. Schwartz Consulting Editor Pocket Guide to Critical Care Pharmacotherapy Second Edition Author John Papadopoulos, B.S.,
More informationMusculoskeletal Health in Women
Musculoskeletal Health in Women Elinor Mody Elizabeth Matzkin Editors Musculoskeletal Health in Women Editors Elinor Mody, MD Department of Rheumatology Gretchen and Edward Fish Center for Women s Health
More informationProgress in Social Psychiatry in Japan
Progress in Social Psychiatry in Japan Yoshibumi Nakane Progress in Social Psychiatry in Japan An Approach to Psychiatric Epidemiology Yoshibumi Nakane Department of Neuropsychiatry Nagasaki University
More informationDating Neurological Injury
Dating Neurological Injury wwwwwwwww Jeff L. Creasy Dating Neurological Injury A Forensic Guide for Radiologists, Other Expert Medical Witnesses, and Attorneys Jeff L. Creasy Associate Professor of Neuroradiology
More informationActive ingredients: Pantoprazole sodium 45.1 mg equivalent to 40 mg Pantoprazole base
Trade name Pantazol Vials for I.V. Injection (infusion) Generic name Pantoprazole sodium sesquihydrate Composition Each l ml re-constituted injectable solution contains: Active ingredients: Pantoprazole
More informationEssentials in Cytopathology Series
Essentials in Cytopathology Series ESSENTIALS IN CYTOPATHOLOGY SERIES Dorothy L. Rosenthal, MD, FIAC, Series Editor 1. D.P. Clark and W.C. Faquin: Thyroid Cytopathology. 2005 ISBN 0-387-23304-0 Douglas
More informationPACKAGE INSERT. 10mg: Each enteric-coated delayed release tablet contains 10 mg of rabeprazole sodium, equivalent
PACKAGE INSERT SCHEDULING STATUS Schedule 4 PROPRIETARY NAME (and dosage form) PARIET 10 mg tablets PARIET 20 mg tablets COMPOSITION 10mg: Each enteric-coated delayed release tablet contains 10 mg of rabeprazole
More informationJeffrey P. Weiss Jerry G. Blaivas Philip E.V. Van Kerrebroeck Alan J. Wein. Editors. Nocturia. Causes, Consequences and Clinical Approaches
Nocturia Jeffrey P. Weiss Jerry G. Blaivas Philip E.V. Van Kerrebroeck Alan J. Wein Editors Nocturia Causes, Consequences and Clinical Approaches Editors Jeffrey P. Weiss, MD, FACS Department of Urology
More informationCentral Nervous System Diseases and Inflammation
Central Nervous System Diseases and Inflammation Thomas E. Lane Monica Carson Conni Bergmann Tony Wyss-Coray Editors Central Nervous System Diseases and Inflammation Thomas E. Lane Center for Immunology
More informationGastric ulcer: The recommended dosage is Pepzol 20 mg once daily. Symptom resolution is rapid and in most
Name Pepzol (Omeprazole) 20 mg, 40 mg Modified release (MR) Capsules Composition Each capsule Contains: Omeprazole 20 mg or 40 mg For excipients see "list of excipients" Pharmaceutical form Pepzol capsules
More informationSPRINGER BRIEFS IN BIOCHEMISTRY AND MOLECULAR BIOLOGY. Gerhard Bauer Joseph S. Anderson. Gene Therapy for HIV From Inception to a Possible Cure
SPRINGER BRIEFS IN BIOCHEMISTRY AND MOLECULAR BIOLOGY Gerhard Bauer Joseph S. Anderson Gene Therapy for HIV From Inception to a Possible Cure 123 SpringerBriefs in Biochemistry and Molecular Biology For
More informationRpts. GENERAL General Schedule (Code GE) Program Prescriber type: Dental Medical Practitioners Nurse practitioners Optometrists Midwives
Esomeprazole 20mg Name, Restriction, Manner of esomeprazole 20 mg enteric tablet, 30 (8886Q) (029W) Gastric ulcer Peptic ulcer Treatment Phase: Initial treatment The therapy must be for initial treatment
More informationPhiladelphia College of Osteopathic Medicine. Shawn P. Mahoney Philadelphia College of Osteopathic Medicine,
Philadelphia College of Osteopathic Medicine DigitalCommons@PCOM PCOM Physician Assistant Studies Student Scholarship Student Dissertations, Theses and Papers 2011 Is Esomeprazole (Nexium) More Effective
More informationZollinger-Ellison Syndrome
Zollinger-Ellison Syndrome National Digestive Diseases Information Clearinghouse U.S. Department of Health and Human Services NATIONAL INSTITUTES OF HEALTH What is Zollinger-Ellison syndrome (ZES)? ZES
More informationOVERALL SUMMARY OF THE SCIENTIFIC EVALUATION OF LOSEC AND ASSOCIATED NAMES (SEE ANNEX I)
ANNEX II SCIENTIFIC CONCLUSIONS AND GROUNDS FOR AMENDMENT OF THE SUMMARY OF PRODUCT CHARACTERISTICS, LABELLING AND PACKAGE LEAFLET PRESENTED BY THE EMEA 21 SCIENTIFIC CONCLUSIONS OVERALL SUMMARY OF THE
More informationRadiation Therapy for Skin Cancer
Radiation Therapy for Skin Cancer Armand B. Cognetta Jr. William M. Mendenhall Editors Radiation Therapy for Skin Cancer Editors Armand B. Cognetta Jr. Dermatology Associates of Tallahassee Chief, Division
More informationProton Pump Inhibitor De-prescribing Guidance
Amendment History Proton Pump Inhibitor De-prescribing Guidance VERSION DATE AMENDMENT HISTORY 1.0 2013 Previous version 2.0 September 2015 Comments Amendment to Flow chart and addition of Rationale page
More informationAlexander N. Sencha Elena V. Evseeva Mikhail S. Mogutov Yury N. Patrunov. Breast Ultrasound
Breast Ultrasound Alexander N. Sencha Elena V. Evseeva Mikhail S. Mogutov Yury N. Patrunov Breast Ultrasound Alexander N. Sencha Department of Ultrasound Diagnostics Yaroslavl Railway Clinic Yaroslavl
More informationAIDS Testing Methodology and Management Issues
AIDS Testing Gerald Schochetman J. Richard George Editors AIDS Testing Methodology and Management Issues Foreword by Walter R. Dowdle With 38 Illustrations Springer-Verlag New York Berlin Heidelberg London
More informationCommunication in Cognitive Behavioral Therapy
Communication in Cognitive Behavioral Therapy Michela Rimondini Editor Communication in Cognitive Behavioral Therapy Editor Michela Rimondini Department of Public Health and Community Medicine University
More informationRABEPRAZOLE Sodium Delayed-Release Tablets, for oral use Initial U.S. Approval: 1999
HIGHLIGHTS OF PRESCRIBING INFORMATION These highlights do not include all the information needed to use rabeprazole sodium delayed-release tablets safely and effectively. See full prescribing information
More informationProgressive Multiple Sclerosis
Progressive Multiple Sclerosis Alastair Wilkins Editor Progressive Multiple Sclerosis Editor Alastair Wilkins, M.A., M.B., B.Chir, Ph.D., FRCP Department of Neurology Frenchay Hospital Bristol UK ISBN
More informationEvidence-Based Forensic Dentistry
Evidence-Based Forensic Dentistry Balwant Rai Jasdeep Kaur Evidence-Based Forensic Dentistry Authors Balwant Rai Earth and Life Sciences Vrije Universiteit Amsterdam and ILEWG Amsterdam The Netherlands
More informationINFORMATION FOR THE CONSUMER
INFORMATION FOR THE CONSUMER IMPORTANT INFORMATION YOU SHOULD KNOW ABOUT NAT-Omeprazole DR (omeprazole magnesium delayed release tablets) Read this leaflet carefully. It contains general points about NAT-Omeprazole
More informationCerebral Blood Flow, Metabolism, and Head Trauma
Cerebral Blood Flow, Metabolism, and Head Trauma Christian W. Kreipke Editors Jose A. Rafols Cerebral Blood Flow, Metabolism, and Head Trauma The Pathotrajectory of Traumatic Brain Injury Editors Christian
More informationDISEASES OF THE GASTROESOPHAGEAL MUCOSA
DISEASES OF THE GASTROESOPHAGEAL MUCOSA CLINICAL GASTROENTEROLOGY George Y. Wu, MD, PhD SERIES EDITOR Diseases of the Gastroesophageal Mucosa: The Acid-Related Disorders, edited by James W. Freston, 2001.
More informationPharmacy Coverage Guidelines are subject to change as new information becomes available.
PROTON PUMP INHIBITORS, NON-PREFERRED FORMS: ACIPHEX (rabeprazole sodium EC) oral tablet ACIPHEX SPRINKLE (rabeprazole sodium DR) oral capsule ESOMEPRAZOLE STRONTIUM (esomeprazole strontium DR) oral capsule
More informationAtlas of Dermatology in Internal Medicine
Atlas of Dermatology in Internal Medicine wwwwwwwwwww Néstor P. Sánchez Editor Atlas of Dermatology in Internal Medicine Editor Néstor P. Sánchez Professor of Dermatology and Dermatopathology and Chairman
More informationSpringerBriefs in Cancer Research
SpringerBriefs in Cancer Research For further volumes: http://www.springer.com/series/10786 Natalia Aptsiauri Angel Miguel Garcia-Lora Teresa Cabrera MHC Class I Antigens In Malignant Cells Immune Escape
More informationPractical Case Studies in Hypertension Management. Series editor Giuliano Tocci Rome, Italy
Practical Case Studies in Hypertension Management Series editor Giuliano Tocci Rome, Italy The aim of the book series Practical Case Studies in Hypertension Management is to provide physicians who treat
More informationAll pharmacodynamic effects observed can be explained by the effect of omeprazole on acid secretion.
OMEPRAZOLE Losec 10mg and 20mg Capsules Acid Pump Inhibitors FORMULATION Each capsule contains Omeprazole 10 mg or 20 mg. PHARMACEUTICAL FORM Omeprazole (LOSEC) capsule 10 mg: hard gelatin capsule with
More informationPATHOLOGY OF MALIGNANT MELANOMA
PATHOLOGY OF MALIGNANT MELANOMA Springer Science+Business Media, LLC PATHOLOGY of MALIGNANT MELANOMA Raymond L. Barnhill, MD Professor of Dermatology and Pathology, Departments of Dermatology and Pathology,
More informationPANSEC I.V. Injection (Pantoprazole)
Published on: 10 Jul 2014 PANSEC I.V. Injection (Pantoprazole) Composition PANSEC I.V. 40 mg Each vial contains: Pantoprazole Sodium Sesquihydrate Equivalent to Pantoprazole...40 mg (As a sterile, freeze-dried
More informationAppropriate Use of Proton Pump Inhibitors (PPIs) Anderson Mabour, Pharm.D., BCPS Clinical Pharmacy Specialist
Appropriate Use of Proton Pump Inhibitors (PPIs) Anderson Mabour, Pharm.D., BCPS Clinical Pharmacy Specialist Disclosures I have no actual or potential conflicts of interest to report in relation to this
More informationTherapeutic rtms in Neurology
Therapeutic rtms in Neurology Thomas Platz Editor Therapeutic rtms in Neurology Principles, Evidence, and Practice Recommendations Editor Thomas Platz BDH-Klinik Greifswald Ernst-Moritz-Arndt Universität
More informationLOSEC MUPS 10 mg, 20 mg and 40 mg Tablets ASTRAZENECA
10-14 LOSEC MUPS 10 mg, 20 mg and 40 mg Tablets ASTRAZENECA omeprazole Tablets Composition Each tablet contains: Omeprazole magnesium 10.3 mg, 20.6 mg and 41.3 mg (corresponding to omeprazole 10 mg, 20
More informationVasilis Vasiliou. Q. Max Guo. Alcohol and Cancer
Alcohol and Cancer Samir Zakhari Editors Vasilis Vasiliou Q. Max Guo Alcohol and Cancer Editors Samir Zakhari, Ph.D. Director Division of Metabolism and Health Effects National Institute on Alcohol Abuse
More informationGastro-oesophageal reflux disease and peptic ulcer disease. By: Dr. Singanamala Suman Assistant Professor Department of Pharm.D
Gastro-oesophageal reflux disease and peptic ulcer disease By: Dr. Singanamala Suman Assistant Professor Department of Pharm.D Gastro-oesophageal reflux disease and peptic ulcer disease Learning objectives:
More informationProton Pump Inhibitors
Market DC Proton Pump Inhibitors Override(s) Prior Authorization Quantity Limit** Approval Duration Preferred PPI: No Prior Authorization required Preferred PPI quantity override: Lifetime Non-Preferred
More informationSeries in Psychopathology. Series Editor Lauren B. Alloy
Series in Psychopathology Series Editor Lauren B. Alloy Michael W. O'Hara Postpartum Depression Causes and Consequences With a Foreword by Lee S. Cohen, M.D. With 22 Illustrations Springer-Verlag New York
More information